Overview

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Status:
Not yet recruiting

Trial end date:
2026-06-01

Target enrollment:

Participant gender:

Summary

This phase II trial tests the accuracy of functional imaging (FFNP)-positron emission tomography (PET)/computed tomography (CT) to predict response to abemaciclib plus endocrine therapy. Abemaciclib is a drug used to treat certain types of hormone receptor positive (HR+), HER2 negative breast cancer. Abemaciclib blocks certain proteins, which may help keep tumor cells from growing. Endocrine therapy adds, blocks, or removes hormones that can cause cancer to grow. FFNP PET imaging is a form of x-ray that uses FFNP as an imaging agent that may provide more precise information about the location of tumors that "light up" with FFNP than a PET scan alone can provide.

Phase:

Phase 2

Details

Lead Sponsor:

University of Washington

Collaborator:

Breast Cancer Research Foundation

Treatments:

Anastrozole
Deoxyglucose
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Exemestane
Fluorides
Fluorodeoxyglucose F18
Fulvestrant
Hormones
Letrozole
Polyestradiol phosphate
Prolactin Release-Inhibiting Factors
Tamoxifen